$5 million upfront with up to an additional $5 million of potential aggregate gross proceeds upon the exercise in full of short-term warrantsWASHINGTON, July 15, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (the “Company” or “60 Degrees”) (Nasdaq: SXTP; SXTPW), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced the pricing of a public offering of 2,631,578 shares of the Company’s common stock (or pre-funded warrants in lieu thereof) and accompa ...

New Drug Application intended for 2026, subject to generation of positive data from three U.S. clinical trials planned or in progressTotal addressable market (TAM) for ARAKODA for Human Babesiosis is informed by results of a 6,000 nationwide patient survey and a quantitative research study involving 300 healthcare professionals WASHINGTON, July 15, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company focused on developing n ...

Data from three independent clinical studies demonstrate utility of tafenoquine to treat acute canine babesiosis WASHINGTON, July 14, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced that the Company will conduct a gap analysis of its existing data prior to submitting a Minor Use Minor Species (MUMS) designation request to the United States Foo ...

New 8-count bottles now available through major retail pharmaciesARAKODA® is the only weekly prophylactic therapy to provide protection against the blood and liver stages of malaria WASHINGTON, June 04, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced the introduction of a new 8-count bottle format for ARAKODA® (tafenoquine). The 8-count bottle ...

25,000 U.S. adults per year claim reimbursement for medical costs associated with babesiosis v. CDC estimates of 2,000A full 45 percent of persistent babesiosis cases include chronic fatigueHealthcare providers treating patients who present with unexplained chronic fatigue may wish to consider babesiosis as a differential diagnosisCompany plans to submit a new drug application (NDA) to FDA in 2026, has two babesiosis clinical trials underway with another anticipated to commence enrollment later this year WA ...

Q1 2024 net product revenues increased 55% year-over-year to $163.6 thousand.Gross profit increased 124% to $90.3 thousand. WASHINGTON, May 15, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, reported today their financial results for the first fiscal quarter of the 2025 year, ended March 31, 2025. Financial Highlights for the Quarter Ended March 31, 2025: Net product revenu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _________ to __________ COMMISSION FILE NUMBER 001-41719 60 DEGREES PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) | Delaware | ...

In a survey representative of the general U.S. adult population, 1.26 percent of respondents – equivalent to about 3 million people – reported having received a medical diagnosis of babesiosis during their life-time; CDC data imply only about 73,000 people in that category.At the time they replied to the survey, 3.7 percent of respondents – equivalent to about 9.9 million people – reported they had been experiencing fatigue, a common symptom of babesiosis, for six months or longer. WASHINGTON, April 22, 202 ...

文章核心观点 60 Degrees Pharmaceuticals首席执行官Geoff Dow将在Healing Lyme Summit上参与关于巴贝虫病管理和治疗的科学讨论，强调其威胁、临床挑战及应对需求，并介绍公司相关临床试验情况 [1][2][3] 公司信息 - 60 Degrees Pharmaceuticals成立于2010年，专注开发和营销治疗及预防传染病的新药，总部位于华盛顿特区，在澳大利亚有多数股权子公司 [6] - 公司在2018年其主打产品ARAKODA®（tafenoquine）获FDA疟疾预防批准，还与美国、澳大利亚和新加坡的知名研究组织合作，使命获美国国防部和私人机构投资者资助 [6] - 公司创始人兼首席执行官Geoff Dow在抗感染产品开发领域有超25年经验，曾在疟疾、登革热等疾病方面开展工作，与美国国防部和多国学术研究机构合作 [5] 行业信息 - 巴贝虫病是一种快速出现的蜱传疾病，常与莱姆病共同感染，在美国的流行率不断上升，但公众和临床对其存在和严重性的认识有限 [1][4] 事件信息 - Healing Lyme Summit是2025年4月15 - 21日举办的免费虚拟活动，聚焦蜱传疾病的诊断和治疗，有每日访谈、科学讲座和教育内容 [4] - Geoff Dow将在活动中强调巴贝虫病威胁、临床挑战，以及提高认识和改善诊断治疗方案的迫切需求，并介绍公司两项评估tafenoquine治疗严重巴贝虫病和免疫抑制患者持续性疾病疗效和安全性的临床试验情况 [2][3] - 注册参与者可在活动期间观看Dow的讨论直播 [4]

文章核心观点 60 Degrees Pharmaceuticals与耶鲁大学医学院和公共卫生学院签署专利许可协议，共同推进tafenoquine用于巴贝虫病治疗和预防的开发与商业化，该药物有望满足巴贝虫病治疗的未满足需求 [1][3] 合作协议 - 60 Degrees Pharmaceuticals与耶鲁大学医学院和公共卫生学院签署专利许可协议，共同推进tafenoquine用于巴贝虫病治疗和预防的开发与商业化 [1] - 此前双方研究人员已开展合作，研究tafenoquine对巴贝虫病的活性 [2] 巴贝虫病及tafenoquine研究 - 巴贝虫病由微小寄生虫Babesia引起，通过黑腿蜱叮咬传播，可能危及老年人和免疫抑制患者生命，每年约47.6万例新感染莱姆病患者中，多达4.76万例可能同时感染巴贝虫 [4] - tafenoquine是治疗复发性巴贝虫病的有前景疗法，含tafenoquine和伯氨喹的8 - 氨基喹啉类药物的疗效和安全性有充分记录 [4] - 60 Degrees Pharmaceuticals赞助的临床试验（NCT06207370）正在评估tafenoquine治疗人类严重巴贝虫病的疗效和安全性，试验在美国多个地点进行，至少招募24至33名患者后进行中期分析 [5] tafenoquine获批情况及特点 - tafenoquine于2018年在美国以ARAKODA®获批用于疟疾预防，2019年商业推出，通过药品批发商网络分销，是处方药 [7] - tafenoquine终末半衰期约16天，可减少疟疾预防用药频率 [7] 60 Degrees Pharmaceuticals公司情况 - 公司成立于2010年，专注于开发和销售治疗及预防传染病的新药，2018年其主打产品ARAKODA®（tafenoquine）获FDA批准用于疟疾预防 [18] - 公司与美国、澳大利亚和新加坡的知名研究机构合作，获得美国国防部和私人机构投资者的实物资金支持 [18]